Do not miss the upcoming EURECA-m e-seminars ‘Sleep Disordered Breathing in CKD: Risk and remedies’ on January 25, 2022 and ‘Revisiting cholesterol lowering in CKD and dialysis – what have the new agents got to offer?’ on February 22, 2022.
Click here to learn more.

New publication in NDT
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease, Alberto Ortiz, Charles Ferro et al.
Click here to watch the video

MISSION

How renal dysfunction engenders cardiovascular complications is still poorly understood. Notwithstanding interest on CKD is on the rise in the medical community at large, renal dysfunction remains a Cinderella in clinical research. To make a concrete example on the systematic overlooking of the cardio-renal link, more often than not, cardiovascular disease trials do not give information on the kidney function of participant patients. Disappointingly, the vast majority of these trials usually exclude patients with renal insufficiency. Even though the situation will probably change in the future, with notable exceptions, by now there are still few concrete signs that cardiovascular trialists take into proper consideration patients with CKD in the design of their studies. Indeed, the history is one of deliberate (but incomplete) exclusion. Even though the number of observational and mechanistic studies at the kidney-heart interface is now conspicuous, specifically designed research focusing on patients with both chronic kidney disease and cardiovascular disease appears to be a priority issue, on both clinical and scientific grounds.

The aim and scope of EURECA-m is to promote collaborations among European centres pursuing research in the overlapping area of cardiovascular and renal medicine.
Congresses are an important instrument for fostering scientific research because facilitate contacts and face to face discussions among clinicians and scientists. Scientific congresses of various sort prospered during the last decades as did scientific societies. Cardio-renal medicine already receives sufficient attention in international meetings by major scientific societies. While promoting communication between members and education (see below) are important goals of EURECA-m, it is not intention of the ERA Working Groups to compete with or replace existing national and international societies (and other WGs) for the organization of congresses. Rather, EURECA-m aims at bonding with these Working Groups by joining and/or endorse well conceived meetings centred on the nephrology – cardiovascular medicine interface. EURECA-m will look rather at creating the opportunity for collaboration among and between nephrologists and other specialists. To this end a special type of Convention priorisiting the presentation of research proposals that have the characteristics of being feasible, relatively low-cost and of clinical relevance will be the centrepiece of the group. Creating shared databases is a concrete example of fruitful collaboration which may address relevant clinical research questions. Several research groups in Europe collected or are collecting 24h ABPM recordings in patients with kidney diseases or with hypertension or heart diseases along with detailed clinical information and outcome data. The same applies to measures of vascular involvement like pulse wave velocity or to cardiac imaging techniques from echocardiography to Nuclear Magnetic Resonance. Large databases are a tremendous opportunity for generating or testing scientific hypotheses. However, collection/merging data requires expertise in clinical epidemiology as well as in data management and statistical analysis. The range of databases that can be built is large and encompasses pre-dialysis and dialysis databases. For this reason EURECA-m will establish a special board of epidemiologists and biostatisticians that will be involved in collaborations of the kind and that will provide methodological input in study design, data collection/merging and statistical analysis. Investigator-initiated trials embedded in clinical practice represent another new possibility for effective collaboration among research groups aimed at advancing knowledge on cardio-renal medicine. Furthermore, basic scientists aimed at moving their bench observations into the clinical realm may find useful to present their data and ideas to clinical investigators that may help their research work entering the translational phase.

Promoting collaboration between different specialities: a step by step approach.
Collaborations between investigators from different specialties and effective bridging of interspecialty knowledge are complex issues which pose diverse challenges, from differences in the perception of priorities to difficulties related with setting common goals. EURECA-m will make a special effort to contribute at building up a common territory for nephrologists, cardiologists, hypertensionologists and diabetologists.

Identification of research priorities and education on cardiovascular and renal medicine.
While the ultimate goal of medical research is producing better clinical care, research is also an expression of freedom, serendipity and intellectual curiosity. Individual investigators pursue their research driven by their scientific interest and background and by external factors such as the academic environment where they work, funding and other considerations. It is widely perceived that identifying areas where research is most needed may serve to improve clinical medicine and help investigators at setting their aims and goals. This is a complex endeavour that can be accomplished by thorough analysis of existing knowledge face to face with major clinical problems in pertinent areas. Such an exercise is typically made by methodologists and guidelines developers after extensive literature review and careful consideration of the epidemiology and the clinical and public health impact of the conditions being analysed. Producing position statements and setting recommendations on priority research topics in the area of cardio-renal medicine is a goal of EURECA-m. In this respect, the European Renal Best Practice (ERBP) group by the ERA has successfully started producing documents which provide guidance to the clinicians in everyday clinical practice. To avoid duplication of efforts and to prevent overlapping with ERBP activities, a collaboration scheme will be proposed to ERBP whereby proposals for position statements and documents of general interest by EURECA-M will be submitted and reviewed by ERBP.
EURECA-m aims at being useful to ERA members and nephrologists in general. Therefore education is an important goal of this Working Groups. Educational endeavours by EURECA-m will prioritise courses on methodology and application of state of art instrumentation useful for research in this area. Special courses/meetings to support collaborative research projects will be designed when these approach the implementation phase.

BOARD

Francesca Mallamaci (Italy) – Chair
Charles J. Ferro (United Kingdom) – Vice-Chair
Olga Balafa (Greece)
Lucia Del Vecchio (Italy)
Beatriz Fernandez Fernandez (Spain)
Robert Ekart (Slovenia)
Patrick Mark (United Kingdom)

Evangelia Ntounousi (Greece)
Patrick Rossignol (France)
José Manuel Valdivielso (Spain)

HOW TO JOIN THE WORKING GROUP

Being a ordinary member of the EURECA-m Working Group means being part of a network which facilitates exchanges of ideas on basic science research and new treatment protocols.

Becoming an ordinary member of the EURECA-m Working Group is FREE OF CHARGE. Ordinary members must be ERA members and be persons with a proven interest in the research area covered by the WG. Exceptions are possible only for non-nephrologists.

By joining the EURECA-m Working Group you will receive constant updates on the Working Group initiatives be included in the Directory of EURECA-m Working Groups’ ordinary members and start networking with colleagues from all over the world.

Click here to join.

The ordinary membership application is subject to validation. Please allow some time for a quick administrative check before applying multiple times.

PUBLICATIONS

Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new erahas already begun.
Journal of Hypertension, June 2021

Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
Nephrology Dialysis Transplantation, May 2021 – Click here to watch the related NDT Author Video

Same rhythm, different song—approaches to atrial fibrillation management by cardiologists and nephrologists
Clinical Kidney Journal, January 2021

Intravenous iron therapy and the cardiovascular system: risks and benefits
Clinical Kidney Journal, November 2020

Treatment of resistant hypertension in the hemodialysis population: a 44-h ambulatory BP Monitoring (ABPM) Study
Journal of Hypertension, September 2020

Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey
EP Europace, March 2020

Prognostic values of left ventricular mass index in chronic kidney disease patients
Nephrology Dialysis Transplantation, December 2019

Is blood pressure measured correctly in dialysis centres? Physicians’ and patients’ views 
Nephrology Dialysis Transplantation, September 2019

Apparent treatment-resistant hypertension in the hemodialysis population
Hypertension, July 2019

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Nephrology Dialysis Transplantation, February 2019

Lipid management in patients with chronic kidney disease
Nature Reviews Nephrology, December 2018

Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA
Nephrology Dialysis Transplantation, July 2018

Pulse Wave Velocity and Prognosis in End-Stage Kidney Disease
Hypertension. June 2018

Validation of echocardiographic criteria for the clinical diagnosis of heart failure in chronic kidney disease
Nephrology Dialysis Transplantation, July 2018

The systemic nature of CKD
Nature Reviews Nephrology, June 2017

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).
J Hypertens. April 2017

Optimizing hypertension management in renal transplantation: a call to action
Nephrology Dialysis Transplantation,  November 2017

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).
Nephrology Dialysis Transplantation, April 2017

Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project.
Nephrology Dialysis Transplantation, December 2016

Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure
Kidney International, December 2016

Clinical management of the uraemic syndrome in chronic kidney disease.
Lancet Diabetes Endocrinol. March 2016

The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study.
Clin J Am Soc Nephrol. November 2016

Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns.
Hypertension, May 2016

Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles.
Hypertension. June 2016

Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research.
Hypertension. July 2015

The double challenge of resistant hypertension and chronic kidney disease.
Lancet. 2015 ;386(10003):1588-98.

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure..
Lancet. 2014 May 24;383(9931):1831-43.

Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?
Nephrol Dial Transplant. 2014 Jul;29(7):1275-84.

Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry.
Nephrol Dial Transplant. 2014 Feb;29(2):232-9.

Pulmonary hypertension in CKD.
Am J Kidney Dis. 2013 Apr;61(4):612-22.

ONGOING PROJECTS

Over the last 3 years considerable strides have been made to consolidate the ongoing EURECA-m projects. Several opinion and consensus documents have been published in major journals (see below) having brought together the gathered expertise of EURECA-m Board members.

Lipid management in patients with chronic kidney disease this project involving current and past members of the EURECA-m Board took 2 years to be complete but has now been accepted for publication in Nature Reviews in Nephrology. It is a massive document (>12000 words with >300 references) summarising the current state of knowledge on lipids in CKD/ESRD, assessing the potential impact of emerging lipid-modifying therapies and providing a critical appraisal of the now 5 year old guidelines produced by KDIGO.

The LUST Trial boasts the recruitment with 418 patients enrolled in a study in which centres from 20 European countries participated. Click here to read the protocol. The study will officially end in March 2020.  Click here to read all related publications.

The EURECA-m ABPM Registry now has 6 participating centres with data from over 500 patients collected. Preliminary data was presented at the 2018 ERA Congress with a full paper published in NDT. So far, 28 papers have been published on behalf of the EURECA-m Working Group. The group recently published the paper Apparent treatment-resistant hypertension in the hemodialysis population in the Journal of Hypertention.

EVENTS

Sleep Disordered Breathing in CKD: Risk and remedies
ERA WG e-seminar #18 – organised by EURECA-m
Tuesday January 25, 2022 at 5 PM CET
New York 11 AM / San Francisco 8 AM / Buenos Aires 12 AM / Rio de Janeiro 10 AM / London 4 PM / Moscow 6 PM / New Delhi 8.30 PM / Jakarta 10 PM / Beijing 11 PM / Sydney Friday 1 AM

Speaker
Francesca Mallamaci, IT

Panelists
Charles Ferro, UK
Alberto Ortiz, ES

Moderator
Olga Balafa, GR


Revisiting cholesterol lowering in CKD and dialysis – what have the new agents got to offer?
ERA WG e-seminar #20 – organised by EURECA-m
Tuesday February 22 at 5 PM CET
New York 11 AM / San Francisco 8 AM / Buenos Aires 12 AM / Rio de Janeiro 10 AM / London 4 PM / Moscow 6 PM / New Delhi 8.30 PM / Jakarta 10 PM / Beijing 11 PM / Sydney Friday 1 AM

Speaker
Francesca Mallamaci, IT

Panelists
Charles Ferro, UK
Alberto Ortiz, ES

Moderator
Olga Balafa, GR

The WG e-seminars are accessible free of charge to ERA members only. The registration is possible by accessing My ERA digital area in ‘My CME Courses’ section.

ECMEC® credits available for ERA Members participating LIVE.

WEBCASTS

Revisiting cholesterol lowering in CKD and dialysis – what have the new agents got to offer?

ERA WG e-seminar series #20 – organised by EURECA-m
Click here to watch the webcast of the event


Sleep Disordered Breathing in CKD: Risk and remedies
ERA WG e-seminar series #18 – organised by EURECA-m
Click here to watch the webcast of the event


Target BP in CKD patients in the post SPRINT era
ERA WG e-seminar series #3 – organised by EURECA-m
Click here to watch the webcast of the event


Assessing fluid status in dialysis – is lung ultrasound the emerging gold standard? – March 4, 2021
ERA WG e-seminar series #3 – organised by EURECA-m
Click here to watch the webcast of the event


Intravenous iron therapy and the cardiovascular system: risks and benefits – November 26, 2020
CKJ Journal Club e-seminars #2
Click here to watch the webcast of the event

PAST EVENTS

EURECA-m CME – October 2, 2017 – Taormina, Italy
EURECA-m and CKD-MBD meeting – September 13-15, 2018 – Thessaloniki, Greece
EURECA-m CME – September 16-17, 2016 – Paris, France

Contacts

Links and attachments